Drugs / Insulin glargine HOE901
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01349855 | Mar → May 2011 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03359837 | Jan 2018 → Jun 2020 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02273180 Background | Oct 2014 → Dec 2015 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin glargine HOE901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01349855 ↗ |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT01349855 ↗ |